Anti-HER2 agents, including trastuzumab (an anti-HER2 monoclonal antibody) and HER2-targeted tyrosine kinase inhibitors (TKIs), have demonstrated efficacy in patients with HER2-positive endometrial cancer patients [25]. Here, ERBB2 is linked to endometrial cancer.